大唐药业(836433) - 2022 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2022 was CNY 157,696,440, a decrease of 33.15% compared to the previous year[3] - Net profit attributable to shareholders was CNY 14,107,469, down 77.23% year-on-year[3] - Basic earnings per share decreased to CNY 0.05, representing an 88.37% decline from the previous year[3] - Total assets at the end of the reporting period were CNY 646,451,202, a decrease of 5.98% year-on-year[5] - Shareholders' equity attributable to the company was CNY 481,875,385.76, down 10.26% compared to the beginning of the year[5] - The company's net asset per share decreased to CNY 1.85, a 50% decline year-on-year[5] Impact of COVID-19 - The decline in revenue and net profit was primarily due to the severe impact of COVID-19 outbreaks in Hohhot, affecting normal production and sales[6] - The company expects normal production operations to resume following the pandemic disruptions[6] Corporate Actions - The company implemented a stock dividend, increasing shares by 80% and distributing CNY 5 cash for every 10 shares held[6] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[7]